Low-Risk MDS: What To Do?
Автор: Chadi Nabhan and Healthcare Unfiltered
Загружено: 2025-10-28
Просмотров: 2326
Returning guest Dr. Amer Zeidan of Yale Medicine and Smilow Cancer Hospital joins to discuss how clinicians should approach low-risk Myelodysplastic Syndrome (MDS), which is most often managed in community settings. He breaks down how to risk-stratify patients using molecular and prognostic markers, when to treat versus observe, and his preferred first-line therapies in today’s landscape. Dr. Zeidan also delves into the COMMANDS trial and the role of luspatercept, emerging questions shaping the future of low-risk MDS management, and offers a preview of high-risk MDS developments, including insights from the VERONA study.
Check out my two books: The Cancer journey and Toxic Exposure, available everywhere.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
